[1]李虎子,贾英杰,孔凡铭,等.改良RECIST标准更适用经TACE治疗的肝癌患者的预后评价[J].介入放射学杂志,2016,(01):29-33.
　LI Hu- zi,JIA Ying- jie,KONG Fan- ming,et al.Evaluation of modified RECIST criteria in predicting the prognosis of HCC patients treated with TACE[J].journal interventional radiology,2016,(01):29-33.
点击复制

改良RECIST标准更适用经TACE治疗的肝癌患者的预后评价 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年01期
页码:
29-33
栏目:
肿瘤介入
出版日期:
2016-01-25

文章信息/Info

Title:
Evaluation of modified RECIST criteria in predicting the prognosis of HCC patients treated with TACE
作者:
李虎子;  贾英杰;  孔凡铭;  方文岩;  赵 成;  姜付显
Author(s):
LI Hu- zi;  JIA Ying- jie;  KONG Fan- ming;  FANG Wen- yan;  ZHAO Cheng;  JIANG Fu- xian
Department of Oncology， First Teaching Hospital of Tianjin University of Traditional Chinese Medicine， Tianjin 300193， China
关键词:
【关键词】 肝癌;  疗效评价;  选择性肝动脉栓塞
文献标志码:
A
摘要:
【摘要】 目的 本研究拟确定采用哪一种短期疗效评价标准能够客观、有效、准确地预测经TACE治疗的肝癌患者的预后。方法 回顾性分析59例行TACE治疗的肝癌患者，收集治疗前及治疗后1个月的增强CT或增强MRI影像学资料。分别依据RECIST 1.1标准和mRECIST标准行短期疗效评价，分析两种标准评价结果的一致性；然后依据不同的评价结果，将所有患者分为有效组和无效组，分别分析两组患者中位生存时间和2年生存率的差异。结果 对所有患者进行短期疗效评价，依据RECIST 1.1标准评价为CR、PR、SD、PD的患者；依据mRECIST标准评价为CR、PR、SD、PD的患者；两种标准内部一致性极差（κ=0.19，95%CI，0.16~0.26）。依据RECIST 1.1标准，有效组和无效组患者中位生存时间分别为25个月和20个月，2年生存率分别为62%和80%，两组差异无统计学意义（P>0.05）；依据mRECIST标准，有效组和无效组患者中位生存时间分别为25个月和14个月，2年生存率分别为84%和68%，两组差异有显著统计学意义（P<0.001）。多因素分析，mRECIST标准评价结果是预后的独立预测因素（P=0.02）。结论 采用mRECIST标准评价经TACE治疗的肝癌患者较RECIST标准更有优势。

参考文献/References:

［1］ Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline （version 1.1）［J］. Eur J Cancer, 2009, 45: 228- 247.
［2］ Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. European Association for the Study of the Liver［J］. J Hepatol, 2001, 35: 421- 430.
［3］ Lencioni R, Llovet JM. Modified RECIST （mRECIST） assessment for hepatocellular carcinoma［J］. Semin Liver Dis, 2010, 30: 52- 60.
［4］ World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment［M］. Geneva: World Health Organization, 1979.
［5］ Jaffe CC. Measures of response: RECIST, WHO, and new alter- natives［J］. J Clin Oncol, 2006, 24: 3245- 3251.
［6］ Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada［J］. J Natl Cancer Inst, 2000, 92: 205- 216.
［7］ Sala M, Llovet JM, Vilana R, et al. Initial response to percu- taneous ablation predicts survival in patients with hepatocellular carcinoma［J］. Hepatology, 2004, 40: 1352- 1360.
［8］ Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models［J］. Radiology, 2012, 262: 708- 718.
［9］ Li H, Guo Z, Si T, et al. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation［J］. Eur J Gastroenterol Hepatol, 2013, 25: 620- 627.
［10］ Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor res- ponse by response evaluation criteria in solid tumors （RECIST） and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma［J］. Cancer, 2012, 118: 147- 156.
［11］ 丁 婕， 戴 旭， 苏红英， 等． RECIST 1.0和mRECIST在原发性肝癌TACE术后疗效评价中的对比研究［J］． 中国临床医学影像杂志， 2014， 25： 623- 626．
［12］ Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma［J］. JAMA, 2010, 303: 1062- 1069.
［13］ 李虎子， 郭 志， 王海涛， 等． 肝细胞癌患者TACE后外周血调节性T细胞水平对预后的影响［J］． 介入放射学杂志， 2012， 21： 998- 1001．
［14］ 王黎洲， 李 兴， 宋 杰， 等． 血管内皮生长因子基因型对介入化疗栓塞治疗原发性肝癌预后的评估［J］． 介入放射学杂志， 2015， 24： 396- 399．

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(01):177.
[2]宋锦文,印建国,杨 艳,等. 大直径球囊扩张治疗80例贲门失弛缓症的中远期疗效评价分析[J].介入放射学杂志,2011,(12):1000.
　SONG Jin-wen,YIN Jian-guo,YANG Yan,et al.Large-diameter balloon dilation for the treatment of achalasia of cardia: an analysis of mid-to-long term efficacy in 80 cases[J].journal interventional radiology,2011,(01):1000.
[3]吕维富,张行明,张学彬,等.气管支架置入术治疗重症气道狭窄的疗效与经验[J].介入放射学杂志,2006,(03):163.
　LV Wei-fu,ZHANG Xing-ming,ZHANG Xue-bin,et al.The therapeutic effects and experience of tracheal stent implantation in managing severe tracheal stenosis[J].journal interventional radiology,2006,(01):163.
[4]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(01):348.
[5]赵洪伟,刘福全,岳振东,等.介入治疗8例肝豆状核变性并发严重门静脉高压的疗效[J].介入放射学杂志,2011,(03):224.
　ZHAO Hong-wei,LIU Fu-quan,YUE Zhen-dong,et al.Interventional treatment of severe portal hypertension due to hepatolenticular degeneration therapeutic evaluation of 8 cases[J].journal interventional radiology,2011,(01):224.
[6]李茂全,颜志平,王建华,等.胃癌介入治疗的疗效评价探讨[J].介入放射学杂志,2000,(01):28.
[7]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(01):322.
[8]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(01):968.
[9]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
　AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(01):1010.
[10]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
　DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(01):75.

备注/Memo

备注/Memo:
（收稿日期：２０１5-０6-24）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2016-01-22